Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Total revenue is expected to decline by a mid-single digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis ...

Reports Q4 revenue $2.5B, consensus $2.42B. President and CEO Christopher A. Viehbacher said: “We believe 2024 was an important year on our ...

Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line. The biotechnology pioneer on Wednesday said it logged net income of $266 ...

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...